Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH versus thyroid hormone withdrawal before I-131 remnant ablation in differentiated thyroid cancer
NL-OMON36661Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label trial of thyrotropin alfa and iodine-131 in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Successful ablation and Successful ablation in patients receiving second high-dose I-131. Planned start Oct 2009; status: withdrawn.
02
Drugs
thyrotropin alfaiodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on NL-OMON36661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36661.